ESR1 and osteosarcoma: In contrast, the considerable knockdown of DSCAM-AS1 in ERα-negative HEC-1B cells resulted in significant growth inhibition, being in line with the results of various in vitro studies on cell lines of different tumor entities like non-small cell lung cancer, colorectal cancer, osteosarcoma, hepatocellular carcinoma and melanoma, [20,48,49,50,51], suggesting that the oncogenic action of this lncRNA is not dependent on the presence of ERα, but is upregulated by this receptor in estrogen-responsive cancer and cell lines (endometrial, cervical and breast cancer) [14,24].